# Tapering of Inhaled Corticosteroids in Tezepelumab-treated Asthma patieNts: Impact on Clinical Outcomes

> **NCT07713498** · — · ENROLLING_BY_INVITATION · sponsor: **Franciscus Gasthuis** · enrollment: 61 (estimated)

## Conditions studied

- Severe Asthma

## Interventions

- **OTHER:** Tapering of inhaled corticosteroid (ICS) treatment

## Key facts

- **NCT ID:** NCT07713498
- **Lead sponsor:** Franciscus Gasthuis
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-05-01
- **Primary completion:** 2027-10
- **Final completion:** 2027-10
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2026-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07713498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07713498, "Tapering of Inhaled Corticosteroids in Tezepelumab-treated Asthma patieNts: Impact on Clinical Outcomes". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07713498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*